ALDX
Price
$4.75
Change
-$0.00 (-0.00%)
Updated
Nov 12 closing price
113 days until earnings call
CHRS
Price
$0.82
Change
-$0.00 (-0.00%)
Updated
Nov 12 closing price
106 days until earnings call
Ad is loading...

ALDX vs CHRS

Header iconALDX vs CHRS Comparison
Open Charts ALDX vs CHRSBanner chart's image
Aldeyra Therapeutics
Price$4.75
Change-$0.00 (-0.00%)
Volume$795.55K
CapitalizationN/A
Coherus BioSciences
Price$0.82
Change-$0.00 (-0.00%)
Volume$3.56M
CapitalizationN/A
ALDX vs CHRS Comparison Chart
Loading...
ALDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
CHRS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ALDX vs. CHRS commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALDX is a Hold and CHRS is a Buy.

COMPARISON
Comparison
Nov 14, 2024
Stock price -- (ALDX: $4.76 vs. CHRS: $0.82)
Brand notoriety: ALDX and CHRS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALDX: 186% vs. CHRS: 126%
Market capitalization -- ALDX: $262.32M vs. CHRS: $89.75M
ALDX [@Biotechnology] is valued at $262.32M. CHRS’s [@Biotechnology] market capitalization is $89.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $473.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.83B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALDX’s FA Score shows that 0 FA rating(s) are green whileCHRS’s FA Score has 0 green FA rating(s).

  • ALDX’s FA Score: 0 green, 5 red.
  • CHRS’s FA Score: 0 green, 5 red.
According to our system of comparison, ALDX is a better buy in the long-term than CHRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALDX’s TA Score shows that 3 TA indicator(s) are bullish while CHRS’s TA Score has 6 bullish TA indicator(s).

  • ALDX’s TA Score: 3 bullish, 6 bearish.
  • CHRS’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, CHRS is a better buy in the short-term than ALDX.

Price Growth

ALDX (@Biotechnology) experienced а -9.68% price change this week, while CHRS (@Biotechnology) price change was +12.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.86%. For the same industry, the average monthly price growth was +5.66%, and the average quarterly price growth was +6.44%.

Reported Earning Dates

ALDX is expected to report earnings on Mar 06, 2025.

CHRS is expected to report earnings on Feb 27, 2025.

Industries' Descriptions

@Biotechnology (-1.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALDX($262M) has a higher market cap than CHRS($89.8M). ALDX YTD gains are higher at: 35.613 vs. CHRS (-75.270). CHRS has higher annual earnings (EBITDA): 12.3M vs. ALDX (-35.59M). CHRS has more cash in the bank: 159M vs. ALDX (120M). ALDX has less debt than CHRS: ALDX (15.6M) vs CHRS (270M). CHRS has higher revenues than ALDX: CHRS (308M) vs ALDX (0).
ALDXCHRSALDX / CHRS
Capitalization262M89.8M292%
EBITDA-35.59M12.3M-289%
Gain YTD35.613-75.270-47%
P/E RatioN/AN/A-
Revenue0308M-
Total Cash120M159M75%
Total Debt15.6M270M6%
FUNDAMENTALS RATINGS
ALDX vs CHRS: Fundamental Ratings
ALDX
CHRS
OUTLOOK RATING
1..100
6855
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
91
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
3994
P/E GROWTH RATING
1..100
10071
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALDX's Valuation (37) in the Biotechnology industry is somewhat better than the same rating for CHRS (91). This means that ALDX’s stock grew somewhat faster than CHRS’s over the last 12 months.

ALDX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CHRS (100). This means that ALDX’s stock grew similarly to CHRS’s over the last 12 months.

ALDX's SMR Rating (95) in the Biotechnology industry is in the same range as CHRS (100). This means that ALDX’s stock grew similarly to CHRS’s over the last 12 months.

ALDX's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for CHRS (94). This means that ALDX’s stock grew somewhat faster than CHRS’s over the last 12 months.

CHRS's P/E Growth Rating (71) in the Biotechnology industry is in the same range as ALDX (100). This means that CHRS’s stock grew similarly to ALDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALDXCHRS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
70%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
69%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 8 days ago
82%
Bullish Trend 6 days ago
73%
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ALDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
CHRS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
KSOAX197.940.97
+0.49%
Kinetics Small Cap Opportunities Adv A
BGRAX8.99N/A
N/A
BlackRock Global Equity Abs Rtn Inv A
WSTCX32.03-0.06
-0.19%
Delaware Ivy Science and Technology C
EGLAX10.37-0.07
-0.67%
Eagle Energy Infrastructure A
WBIRX30.04-0.42
-1.38%
William Blair International Growth R6

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with AURA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then AURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
+5.74%
AURA - CHRS
48%
Loosely correlated
-4.40%
DNLI - CHRS
44%
Loosely correlated
-5.32%
ABCL - CHRS
43%
Loosely correlated
-6.35%
PRME - CHRS
41%
Loosely correlated
-1.59%
BEAM - CHRS
41%
Loosely correlated
-7.94%
More